Antibody binding was blocked in varying degrees by abciximab.

Healthy donor platelets were treated with tirofiban (A) or eptifibatide (B) and then with saturating quantities of abciximab. Antibody binding was then measured by flow cytometry. Values shown on the ordinate are fluorescence intensity obtained with abciximab-coated platelets (gray bars) expressed as a percentage of the signal obtained without abciximab (open bars) and represent the average of triplicate determinations. Brackets indicate 1 SD.